Sign Up to like & get
recommendations!
0
Published in 2018 at "Investigational New Drugs"
DOI: 10.1007/s10637-018-0710-x
Abstract: SummaryLanreotide autogel is a long-acting somatostatin analogue with proven efficacy and safety in patients with well-differentiated (WD) gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) in a prior randomized phase III trial (CLARINET). However, the CLARINET study only enrolled patients…
read more here.
Keywords:
efficacy safety;
analysis;
well differentiated;
korean patients ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2017.10.010
Abstract: PURPOSE Neuroendocrine tumors (NETs) are heterogeneous tumors that arise from the neuroendocrine cells of the digestive tract and other organs, such as the lung, ovary, and thyroid glands. They can be well differentiated or poorly…
read more here.
Keywords:
management;
well differentiated;
neuroendocrine tumors;
gastroenteropancreatic neuroendocrine ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2023.41.4_suppl.644
Abstract: 644 Background: liver metastases (LM) from well-differentiated gastroenteropancreatic neuroendocrine tumors (wd-GEP-NET) can develop in 28-77% of patients (pts) in their lifetime. Multiple treatments can provide radiological and symptomatic response. Our aim was to evaluate responses…
read more here.
Keywords:
response;
differentiated gastroenteropancreatic;
neuroendocrine tumors;
liver metastases ... See more keywords